Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Aug 28, 2017
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Evidence-based treatments for depression include pharmacological and psychological interventions. Within psychological interventions, cognitive behavioral therapy (CBT) is one of the most extensively researched evidence-based approaches for depression (Cuijpers, 2015). However, even if optimal treatment and access to services were available to all patients, the burden of depression would be reduced by only 30% (Andrews et al., 2004). Moreover, as depression represents the disorder with the highest drop-out rates during CBT treatment (36.4%) (Fernandez et al., 2015), and a relapse rate of 54...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • informed consent
- • age between 18 and 70 years
- • diagnosis of a single Episode or recurrent Major depressive disorder (MDD) or dysthymia (verified by the MINI)
- Exclusion Criteria:
- • lifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised ≥ 7), intellectual disability (estimated IQ \< 70) or dementia.
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Marion Hagemann-Goebel, Dr.
Principal Investigator
Asklepios Klinik Nord-Ochsenzoll
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials